ReviewNature reviews. Disease primers2023
Helicobacter pylori infection.
Review in Nature reviews. Disease primers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06318104 (Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Amoxicillin 1g + Clarithromycin 500 mg and Tegoprazan 50 mg vs Amoxicillin 1g + Clarithromycin 500 mg and Esomeprazole 40 mg Twice a Day for 14 Days), which is not on this map. Cited by 546 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Amoxicillin 1g + Clarithromycin 500 mg and Tegoprazan 50 mg vs Amoxicillin 1g + Clarithromycin 500 mg and Esomeprazole 40 mg Twice a Day for 14 Days
Who cites it
546 citing papers in PubMed, 10 syntheses or guidelines pooled it, 1,031 citations in OpenAlex.
- Risk of Gastric Neoplasms in Patients with Autoimmune Gastritis: A Systematic Review and Meta-Analysis.Gut and liver · 2026Pooled it
- Guidelines for the management of Helicobacter pylori infection in Japan: 2024 revised edition.Journal of gastroenterology · 2026Guideline
- Efficacy of swab-based RUT in detecting H. pylori infection: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Assessing the non-inferiority of a 10-day compared with a 14-day vonoprazan-amoxicillin dual therapy regimen for H. pylori eradication: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Pooled it
- Comparative efficacy, safety and compliance with dual, triple and quadruple therapy as the first-line treatment regimens forBMJ open gastroenterology · 2026Pooled it
- Worldwide research trends on theFrontiers in immunology · 2026Pooled it
- Gastric cancer prevention byFrontiers in oncology · 2026Pooled it
- Association between oral diseases and oral Helicobacter pylori infection: A systematic review and meta-analysis.Clinical oral investigations · 2025Pooled it
- Helicobacter pylori Infection and Eradication in Relation to Gastroesophageal Reflux Disease.Journal of gastroenterology and hepatology · 2025Pooled it
- AdjuvantMicrobiology spectrum · 2026Trial
- Precision therapy guided by genotypic antibiotic resistance forWorld journal of gastroenterology · 2025Trial
- Efficacy and Safety of Vonoprazan and High-Dose Amoxicillin Dual Therapy for Rescue Treatment of Helicobacter pylori Infection: A Multicenter Randomized Controlled Trial.United European gastroenterology journal · 2025Trial
- Article
- Article
- Review
- Review
- Helicobacter pylori eradication treatment dispensing in the Irish General Medical Services population from 2012 to 2022: a repeated cross-sectional analysis.International journal of clinical pharmacy · 2026Article
- Prevalence of Gastric Intestinal Metaplasia Among Patients with Active Helicobacter Pylori Infection Served by a Safety-Net Healthcare System.Digestive diseases and sciences · 2026Article
- Review
486 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 8 institutions in 6 countries.
Funding
Abstract
Helicobacter pylori infection causes chronic gastritis, which can progress to severe gastroduodenal pathologies, including peptic ulcer, gastric cancer and gastric mucosa-associated lymphoid tissue lymphoma. H. pylori is usually transmitted in childhood and persists for life if untreated. The infection affects around half of the population in the world but prevalence varies according to location and sanitation standards. H. pylori has unique properties to colonize gastric epithelium in an acidic environment. The pathophysiology of H. pylori infection is dependent on complex bacterial virulence mechanisms and their interaction with the host immune system and environmental factors, resulting in distinct gastritis phenotypes that determine possible progression to different gastroduodenal pathologies. The causative role of H. pylori infection in gastric cancer development presents the opportunity for preventive screen-and-treat strategies. Invasive, endoscopy-based and non-invasive methods, including breath, stool and serological tests, are used in the diagnosis of H. pylori infection. Their use depends on the specific individual patient history and local availability. H. pylori treatment consists of a strong acid suppressant in various combinations with antibiotics and/or bismuth. The dramatic increase in resistance to key antibiotics used in H. pylori eradication demands antibiotic susceptibility testing, surveillance of resistance and antibiotic stewardship.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.